| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advancements in complement inhibition for PNH and primary complement–mediated thrombotic microangiopathy
|
Padilla Kelley, Thalia
|
|
|
9 |
15 |
p. 3937-3945
|
artikel
|
| 2 |
A global survey on practice changes and barriers to the use of direct oral anticoagulants in children
|
Avila, M. Laura
|
|
|
9 |
15 |
p. 3718-3727
|
artikel
|
| 3 |
A revised prognostic model for patients with acute myeloid leukemia and first relapse
|
van der Maas, Niek G.
|
|
|
9 |
15 |
p. 3853-3864
|
artikel
|
| 4 |
BCLAF1 restrains stress responses in hematopoietic stem cells to support expansion and repopulation
|
Crowley, Stephanie J.
|
|
|
9 |
15 |
p. 4043-4057
|
artikel
|
| 5 |
Biomarker signatures for sickle cell pain
|
Gupta, Kalpna
|
|
|
9 |
15 |
p. 3821-3823
|
artikel
|
| 6 |
Blinatumomab use in pediatric B-ALL: where are we now?
|
Hall, Anurekha G.
|
|
|
9 |
15 |
p. 3946-3954
|
artikel
|
| 7 |
Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results
|
Cheson, Bruce D.
|
|
|
9 |
15 |
p. 3750-3753
|
artikel
|
| 8 |
Clec12a is required for the pathogenesis of NUP98::NSD1 AML
|
Mohanty, Sagarajit
|
|
|
9 |
15 |
p. 3887-3899
|
artikel
|
| 9 |
Conflating polycythemia vera with essential thrombocytosis
|
Spivak, Jerry L.
|
|
|
9 |
15 |
p. 4061-4062
|
artikel
|
| 10 |
Drug development for leukemia: comprehensive analysis of clinical trials from first report to drug approval
|
Tjioe, Kellen Cristine
|
|
|
9 |
15 |
p. 3810-3813
|
artikel
|
| 11 |
Dysregulated immune proteins in plasma in the UK Biobank predict multiple myeloma 12 years before clinical diagnosis
|
Fieggen, Joshua
|
|
|
9 |
15 |
p. 3766-3770
|
artikel
|
| 12 |
Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial
|
Shimamura, Akiko
|
|
|
9 |
15 |
p. 3728-3738
|
artikel
|
| 13 |
ESCALATing care? Eltrombopag in pediatric aplastic anemia
|
Glass, Joshua
|
|
|
9 |
15 |
p. 3819-3820
|
artikel
|
| 14 |
Exorcizing the devil of factor VIII inhibitors
|
Moorehead, Paul C.
|
|
|
9 |
15 |
p. 3716-3717
|
artikel
|
| 15 |
Extramedullary myeloma is genomically complex and characterized by near-universal MAPK pathway alterations
|
Zanwar, Saurabh
|
|
|
9 |
15 |
p. 3979-3987
|
artikel
|
| 16 |
Extramedullary plasmacytoma in children is a genetically distinct localized neoplasia curable by surgical resection
|
Oschlies, Ilske
|
|
|
9 |
15 |
p. 3909-3918
|
artikel
|
| 17 |
Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy
|
Ananth, Snegha
|
|
|
9 |
15 |
p. 3832-3836
|
artikel
|
| 18 |
Frontline allo-SCT in MRD-negative, intermediate-risk AML
|
Rodríguez-Arbolí, Eduardo
|
|
|
9 |
15 |
p. 4063-4064
|
artikel
|
| 19 |
Genetic deregulation of REL in germinal center B cells induces generation of a pool of lymphoma precursor cells
|
Prévaud, Léa
|
|
|
9 |
15 |
p. 3676-3688
|
artikel
|
| 20 |
Gut microbiota restoration with oral pooled fecal microbiotherapy after intensive chemotherapy: the phase 1b CIMON trial
|
Malard, Florent
|
|
|
9 |
15 |
p. 3739-3749
|
artikel
|
| 21 |
Inaccuracies of venous thromboembolism risk assessment and prevention practices among medically ill patients
|
Lau, Brandyn D.
|
|
|
9 |
15 |
p. 3929-3936
|
artikel
|
| 22 |
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma
|
Danilov, Alexey V.
|
|
|
9 |
15 |
p. 3754-3765
|
artikel
|
| 23 |
Integrating MRD kinetics with allogeneic SCT decisions in AML
|
Jen, Wei-Ying
|
|
|
9 |
15 |
p. 4065-4066
|
artikel
|
| 24 |
Interpretation of response in BOS: the definitions remain key
|
Williams, Kirsten M.
|
|
|
9 |
15 |
p. 4058-4060
|
artikel
|
| 25 |
Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study
|
Sehgal, Alison
|
|
|
9 |
15 |
p. 3694-3705
|
artikel
|
| 26 |
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial
|
Niemann, Carsten U.
|
|
|
9 |
15 |
p. 3665-3675
|
artikel
|
| 27 |
Molecular inflammatory expression profiles associated with the frequency of pain in individuals with sickle cell disease
|
Mucalo Katunaric, Lana
|
|
|
9 |
15 |
p. 3790-3800
|
artikel
|
| 28 |
Molecular profiling of primary renal diffuse large B-cell lymphoma unravels a proclivity for immune-privileged tropism
|
Künstner, Axel
|
|
|
9 |
15 |
p. 3900-3904
|
artikel
|
| 29 |
Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
|
Adegbite, Benjamin
|
|
|
9 |
15 |
p. 4016-4022
|
artikel
|
| 30 |
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma
|
Shumilov, Evgenii
|
|
|
9 |
15 |
p. 3955-3966
|
artikel
|
| 31 |
Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis
|
Aljawai, Yosra M.
|
|
|
9 |
15 |
p. 4023-4036
|
artikel
|
| 32 |
Patient anti-FVIII drug antibodies bind preferentially to a subset of FVIII covalent states
|
Butera, Diego
|
|
|
9 |
15 |
p. 3706-3715
|
artikel
|
| 33 |
PD-1 inhibition for relapse after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome
|
Magenau, John M.
|
|
|
9 |
15 |
p. 3878-3886
|
artikel
|
| 34 |
Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas
|
Poh, Christina
|
|
|
9 |
15 |
p. 4037-4042
|
artikel
|
| 35 |
Predictive value of free light chain burden in patients with AL amyloidosis treated with bortezomib-based regimens
|
Saunders, Brendan
|
|
|
9 |
15 |
p. 3771-3779
|
artikel
|
| 36 |
PRIDE-FTG advances academic careers of underrepresented early-stage investigators performing blood disorders research
|
Pace, Betty S.
|
|
|
9 |
15 |
p. 3919-3928
|
artikel
|
| 37 |
RAS mutation identifies a poor prognostic molecular subtype of therapy-related myeloid neoplasm
|
Kok, Chung Hoow
|
|
|
9 |
15 |
p. 3814-3818
|
artikel
|
| 38 |
Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma
|
O’Donnell, Elizabeth
|
|
|
9 |
15 |
p. 3780-3789
|
artikel
|
| 39 |
Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL
|
Allan, John N.
|
|
|
9 |
15 |
p. 3801-3809
|
artikel
|
| 40 |
Recurrent thrombosis and major bleeding in children treated for VTE
|
Lenahan, Stephanie F.
|
|
|
9 |
15 |
p. 3824-3831
|
artikel
|
| 41 |
Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study
|
Shumilov, Evgenii
|
|
|
9 |
15 |
p. 3865-3877
|
artikel
|
| 42 |
Single-cell sequencing on PBMCs from patients with HA and HB with inhibitors reveals different immune responses to FVIII and FIX
|
Li, Enhao
|
|
|
9 |
15 |
p. 3967-3978
|
artikel
|
| 43 |
Targeting PD-1 for HCT relapse: an immunologic knife’s edge
|
Shapiro, Roman M.
|
|
|
9 |
15 |
p. 3907-3908
|
artikel
|
| 44 |
T-cell dysfunction during blinatumomab therapy in pediatric acute lymphoblastic leukemia
|
Ma, Julie
|
|
|
9 |
15 |
p. 3689-3693
|
artikel
|
| 45 |
The balancing act after pediatric venous thromboembolism
|
Whitworth, Hilary
|
|
|
9 |
15 |
p. 3905-3906
|
artikel
|
| 46 |
The CLUE postsurgery VTE risk instrument for abdominal and pelvic surgery: validation of patient risk factor component
|
Tikkinen, Kari A. O.
|
|
|
9 |
15 |
p. 3837-3844
|
artikel
|
| 47 |
The SAMD1 transcription factor coordinates hematopoietic lineage differentiation and H3K4 methylation status
|
Schaefer, Meg A.
|
|
|
9 |
15 |
p. 3988-4003
|
artikel
|
| 48 |
Thyroid hormones contribute to JAK/STAT pathway abnormal activation, promoting T-cell lymphoma dissemination
|
Debernardi, Mercedes
|
|
|
9 |
15 |
p. 4067-4080
|
artikel
|
| 49 |
To pursue gene therapy or not? Is it feasible after graft failure in allogeneic hematopoietic cell transplant recipients
|
Sharma, Akshay
|
|
|
9 |
15 |
p. 3845-3852
|
artikel
|
| 50 |
Use of the microfluidic impedance red cell assay in sickle cell disease
|
Patwardhan, Akshay A.
|
|
|
9 |
15 |
p. 4004-4015
|
artikel
|
Tijdschrift beschrijving